First U.S. cholera vax ready for PhIII

PaxVax's single-dose oral cholera vaccine has been cleared by the U.S. FDA to go into Phase III trials. The vaccine, known as PXVX-0200, is a live, attenuated vaccine and is already available in 6 countries. The vaccine requires only a single dose and is effective in just 7 days or so. PaxVax expects to begin studies later in 2012. Kenneth Kelley, chief executive officer of PaxVax, says: "We expect our cholera vaccine will be the first vaccine for cholera available in the United States and the only one-dose oral vaccine in the world." Release

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.